Physician profile
Barry J Efros
NPI 1093879579
$1,219.34
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $115 · 2021: $132 · 2022: $13.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $365.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $333.03 | 2019-2021 | |
| Pfizer INC. | $140.65 | 2019-2020 | |
| Abbvie INC. | $140.47 | 2019-2022 | |
| Amgen INC. | $85.22 | 2019-2020 | |
| Lilly USA, LLC | $43.17 | 2019 | |
| Janssen Biotech, INC. | $38.80 | 2019 | |
| Celgene Corporation | $32.88 | 2019 | |
| Horizon Therapeutics Plc | $13.47 | 2019 | |
| Hikma Pharmaceuticals USA | $12.93 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Efros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.